Incyte· @Incyte · X·· 5 天前精选AI 评分62
AI 导读
Incyte 宣布其研发的口服 ALK2 抑制剂已获 FDA 批准，用于治疗进行性骨化性纤维发育不良（FOP）。该药由 Incyte 开发并授权给 Mirum Pharmaceuticals 负责全球开发与商业化。
推荐理由
Incyte 的 ALK2 抑制剂获 FDA 批准用于罕见病 FOP，读者可了解该适应症首个口服治疗选择的监管进展。
正文
An important milestone for people living with fibrodysplasia ossificans progressiva (FOP). The @FDA has approved an oral ALK2 inhibitor developed by Incyte and licensed to @mirumpharma for worldwide development and commercialization. Learn more in the press release. https://bit.ly/4rxVfza
来源：Incyte · x.com